/ /

  • linkedin
  • Increase Font
  • Sharebar

    European Commission approves adalimumab for paediatric uveitis



    Uveitis is an inflammation of the uvea, which includes the iris, choroid and the ciliary body in the eye. If left untreated, it can lead to vision loss, including cataracts, glaucoma and cystoid macular oedema.

    By some estimates, severe vision loss occurs in 25% to 30% of paediatric uveitis cases, making early diagnosis and treatment essential to preserve vision in children with the disease. Juvenile idiopathic arthritis is the most common systemic disorder associated with uveitis in children, accounting for more than 75% of cases of paediatric anterior uveitis.

    Clinicians have long relied on corticosteroids to treat uveitis. These treatments frequently cause ocular and systemic adverse events, so immunosuppressant therapies, including methotrexate, have emerged as an alternative, or second-line therapy.

    Adalimumab effectively lowers inflammation in multiple disorders.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results